Unprecedented overall survival in patients with 1L ESCC and PD-L1 scores ≥1%1
Key Efficacy Outcome: OS in PD-L1 ≥1%
16.8 months of median overall survival with TEVIMBRA + chemotherapy vs 9.6 months with placebo + chemotherapy
Limitation: Efficacy analysis was not powered for statistical comparison and is descriptive only. No definitive conclusions can be drawn.
3-Year Exploratory Follow-Up: OS in PD-L1 ≥1%
Overall survival sustained over 3 years3
21.3% of patients were alive at 3 years with TEVIMBRA + chemotherapy (95% CI: 16.2-26.9) vs 14.3% with placebo + chemotherapy (95% CI: 10.1-19.2)
Limitation: The 3-year OS analysis was exploratory in nature and was not powered to show statistical significance. Landmark OS rates were estimated using the Kaplan-Meier method. No definitive conclusions can be drawn.
Subgroup Analyses: OS in PD-L1 ≥1%
A consistent trend in overall survival favoring TEVIMBRA + chemotherapy across multiple key subgroups3
Analyses of OS
In patients with 1L, unresectable, locally advanced ESCC and PD-L1 scores ≥1% (n=63):
TEVIMBRA + chemotherapy reported 25.6 months mOS vs 11.5 months mOS with placebo + chemotherapy4
TEVIMBRA + chemotherapy reported 16.3 months mOS vs 9.4 months mOS with placebo + chemotherapy4
‡The race subcategory “Other” included American Indian or Alaska Native, not reported, and unknown.
References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.2.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed February 25, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3. Xu J, Kato K, Hubner R, et al. Adv Ther. Published online March 13, 2025. doi:10.1007/s12325-025-03115-9 4. Yoon HH, Kim SS, Xu J, et al. Abstract and poster
presented at: ASCO Gastrointestinal Cancers Symposium; January 8-10, 2026. San Francisco, CA. Abstract 381, poster D12.